RGC — Regencell Bioscience Holdings Limited stock price, charts and financials

QT10Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
6.05
-0.08-1.31%
OverviewShort InterestFilings
RGCQT10Regencell Bioscience Holdings Limited·NASDAQ
6.05-1.31%
TA
Loading chart...
Screen all →
SUPN-5.98%$43.25BHC-8.00%$6.44HCM+0.17%$11.57INDV-2.33%$36.50OCTVV+2.29%$17.40ANIP-1.07%$79.20AMRX-1.96%$18.48PRGO+0.94%$10.78
Snapshot
Index-P/E-EPS (ttm)-Insider Own10.93%Shs Outstand495.47MPerf Week1.34%
Market Cap3.00BForward P/E-EPS next Y-Insider Trans0.00%Shs Float17.28MPerf Month7.84%
Enterprise Value2.99BPEG4.49EPS next Q-Inst Own-Short Float0.19%Perf Quarter-77.89%
Income-4.00MP/S0.00EPS this Y-Inst Trans-Short Ratio3.61Perf Half Y-78.61%
Sales0.00P/B-EPS next Y-ROA-233.91%Short Interest930.08KPerf YTD-71.19%
Book/sh0.01P/C-EPS next 5Y-ROE-231.87%52W High68.99 -91.23%Perf Year-53.35%
Cash/sh0.01P/FCF-EPS past 3/5Y-ROIC-444.21%52W Low4.51 34.15%Perf 3Y1131.38%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility10.64% 12.95%Perf 5Y2454.47%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-124.71%Oper. Margin0.00%ATR (14)0.97Perf 10Y-
Dividend Ex-DateFeb 15, 2018Quick Ratio1.42Sales Y/Y TTM-Profit Margin0.00%RSI (14)37.43Recom3.00
Dividend Gr. 3/5Y-37.00% -23.51%Current Ratio1.42EPS Q/Q-SMA205.86%Beta1.51Target Price-
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-48.99%Rel Volume0.79Prev Close6.13
Employees10LT Debt/Eq-EarningsOct 28SMA200-71.20%Avg Volume288.43KPrice6.05
IPO DateJul 16, 2021Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA0.28Volume229,013Change-1.31%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-02-18DowngradeB. RileyBuy → Neutral
Dec-06-17DowngradeMacquarieOutperform → Neutral
Dec-06-17DowngradeRBC CapitalOutperform → Perform
Dec-06-17UpgradeMoffett NathansonSell → Neutral
Latest News
Company

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
6/30/2025
FY 2024
6/30/2024
FY 2023
6/30/2023
FY 2022
6/30/2022
FY 2021
6/30/2021
FY 2020
6/30/2020
FY 2019
6/30/2019
Total Revenue
0000000
Cost of Goods Sold Incl. D&A0111000
Gross Profit0-1-1-1000
Selling, General and Administrative Excl. Other2355100
Research and Development1123000
Other Operating Expense00-10010
Operating Income-4-5-6-8-1-10
Interest Expense
0000000
Unusual Expense
———————
Non-Operating Income (Expense)
0000000
Net Income Before Taxes-4-4-6-8-1-10
Income Taxes
0000000
Consolidated Net Income-4-4-6-7-1-10
Net Income From Continuing Operations-4-4-6-8-1-10
Net Income-4-4-6-7-1-10
EPS (Recurring)-0.01-0.01-0.01-0.02-0.00-0.00-0.00
EPS (Basic, Before Extraordinaries)-0.01-0.01-0.01-0.02-0.00-0.00-0.00
EPS (Diluted)-0.01-0.01-0.01-0.02-0.00-0.00-0.00
EBITDA-3-4-5-7-1-10
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding494494494494480480480
Market Capitalization8,41844300450———
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$88.98$65.19$41.39$17.59$-6.20● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BELL THOMAS D JRDirectorAug 29 '17Buy14.7625,000369,000126,939Aug 29
KAPLAN STEPHEN ADirectorAug 25 '17Buy14.8710,000148,700155,572Aug 28
Ownby DavidEVP, CFO and TreasurerAug 24 '17Buy14.047,500105,300229,573Aug 24
DUNN GREGORY WPresident and COOMar 09 '17Sale22.1526,050577,00867,052Mar 10
BRANDOW PETER BEVP, General Counsel, Sec.Mar 09 '17Sale22.5020,233455,243212,715Mar 10
ANSCHUTZ PHILIP F10% OwnerNov 23 '16Sale22.9513,000,000298,350,0000Nov 23
DUNN GREGORY WPresident and COOSep 07 '16Sale21.7530,765669,13974,151Sep 08
ANSCHUTZ PHILIP F10% OwnerAug 08 '16Sale21.6013,000,000280,800,0000Aug 08
BRANDOW PETER BEVP, General Counsel, Sec.Jun 29 '16Sale21.5149,0241,054,506219,028Jun 29
DUNN GREGORY WPresident and COOJun 15 '16Sale20.2825,000507,000104,916Jun 17
MILES AMY ECEOMar 15 '16Sale20.8228,201587,145588,405Mar 16
MILES AMY ECEOMar 14 '16Sale21.2275,0001,591,500616,606Mar 16
DUNN GREGORY WPresident and COOMay 19 '15Sale21.4019,000406,600109,724May 20
Weigand Nestor R JrDirectorMar 13 '15Buy22.54881,98752,837Apr 13
YEMENIDJIAN ALEXDirectorFeb 18 '15Sale23.3758,4751,366,5485,241Feb 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.